Eureka Therapeutics to Present at Two Upcoming Virtual Conferences

Oct. 13, 2020 12:00 UTC



EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October:

  • TCR-based Therapies Summit
    ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors
    Speaker: Cheng Liu, Ph.D., President and CEO
    Date: Tuesday, October 27, 2020
    Time: 9:00 a.m. EST
  • Cell & Gene Therapy Bioprocessing & Commercialization
    Optimizing Viral Vector Production
    Speaker: Nicole Nunez, Ph.D., Process Development Scientist
    Date: Thursday, October 22, 2020
    Time: 8:00 a.m. EST


Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit


Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations

KKH Advisors
Kimberly Ha


Source: Eureka Therapeutics, Inc.

Back to news